Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
53 Results for "
Vedotin
" in MedChemExpress (MCE) Product Catalog:
Products (53)
53 Results for "Vedotin" in MCE Product Catalog:
97
97 Publications Verification
Synonyms: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
Research Areas:
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
5
Target:
Research Areas:
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity .
4
4 Cited Publications
Cat. No.: HY-P99016
CAS No.: 1448664-46-7
Target:
Research Areas:
3
3
3 Cited Publications
Cat. No.: HY-P99042
CAS No.: 2279068-37-8
Research Areas:
2
2
Target:
Research Areas:
2
2 Cited Publications
Synonyms: CDX-011; CR011-vcMMAE
Research Areas:
Glembatumumab vedotin (CDX-011) is an ADC comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
1
1 Cited Publications
Cat. No.: HY-P99016B
CAS No.: 1346452-25-2
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P99107A
CAS No.: 914088-09-8
Research Areas:
Brentuximab vedotin (solution) (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). The antibody portion is Brentuximab (HY-P99151), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Brentuximab vedotin (solution) inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin (solution) can be used for the research of relapsed and refractory Hodgkin lymphoma .
1
1 Cited Publications
Cat. No.: HY-P99016A
CAS No.: 1346452-25-2
1
1 Cited Publications
Cat. No.: HY-P99205
CAS No.: 1020264-78-1
Target:
Research Areas:
1
1 Cited Publications
Research Areas:
1
Target:
Research Areas:
1
1 Cited Publications
1
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P99271
CAS No.: 1418628-81-5
Synonyms: Anti-Human F3 Recombinant Antibody
Target:
Research Areas:
1
Target:
Research Areas:
Target:
Research Areas:
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer .
Cat. No.: HY-P990673
Synonyms: DSTP-3086S Antibody; RG-7450 Antibody
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
